HBICE® Bi/Multi-Specific

Step one

Antibody Discovery

Leveraging Harbour Mice® platforms and expertise, Nona provides a complete solution for fully human H2L2, HCAb, and bi/multi-specific antibody discovery, including antigen preparations, immunization, antibody screening, engineering, and functional evaluation.

Step two

ADC Bioconjugation

Nona offers a variety of bioconjugation technologies such as lysine/cysteine-based conjugation with optimized DAR value and optimization of reaction conditions. Our proprietary DAR2 site-specific conjugation and linker-payload library include the majority of classical linker-payloads, like cleavable and non-cleavable linkers.

step Three

ADC Biophysical Characterizations

Based on Nona’s deep understanding of ADC molecules, we perform a comprehensive assessment of molecules for lead identification and characterization, including DAR determination, conjugation stability, plasma stability and drug-releasing efficiency.


HCAb-Based Immune Cell Engager

Nona Biosciences’ proprietary HBICE® (HCAb-Based Immune Cell Engager) platform, built upon Harbour Mice® platforms, enables the development of novel bispecific, multispecific and multivalent antibodies with simplified structures, smaller molecule size, and fewer polypeptide chains. With the HBICE® platform, we can quickly create multispecific antibodies that redirect immune cells to the tumor microenvironment (TME) for effective tumor eradication.

HBICE® molecules are designed to recognize and bind specific tumor-associated antigens (TAAs) on tumor cells, as well as CD3 on T cells or other stimulatory molecules on immune cells like NK cells or myeloid cells. This dual recognition leads to the activation of immune cells within the TME, selectively engaging anti-tumor immunity while avoiding non-specific activation of peripheral immune cells. Furthermore, the HBICE® technology allows for the generation of molecules with different structure and avidities, enabling unique mechanisms of action that cannot be achieved by combination therapies.

The diagrams below depict illustrative scenarios: by circumventing the conventional T-cell activation pathway, typically mediated by the TCR-MHC interaction, HBICE® molecules with CD3-targeting capabilities can induce a broad T-cell response that is not restricted by MHC, effectively overcoming immune escape mechanisms like antigen presentation downregulation. Within the tumor microenvironment (TME), T cells often lack essential costimulatory signals for optimal functionality. HBICE® antibodies, designed to target tumor-associated antigens (TAAs) and provide the essential costimulatory signal for full T cell activation in TAA-dependent manner. This mechanism results in the effective eradication of tumors and an enhanced safety profile.

Figure 1: Novel HBICE®



Explore Our Other High Lighted Technologies

Explore our lorem ipsum

Start your Harbour Mice HCAb PLUS™ Project

Having questions? Contact us at


Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from - Youtube
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound